The global induced pluripotent stem cells market has been growing rapidly owing to the increased research and development activities taking place in the field of regenerative medicine across the globe. iPSCs have the ability to differentiate themselves into various cell types and can prove to be valuable in understanding disease mechanisms and discovering new therapeutic strategies. Their application in drug discovery, development of disease models and toxicity testing has further augmented market growth.

Some of the key advantages of iPSCs include the ability to generate patient and disease-specific stem cells which improves the success rate of transplantation. They can also help reduce the dependence on embryonic stem cells for research purposes. Additionally, iPSCs offer hope for developing therapeutic strategies for incurable diseases like Parkinson's, diabetes, spinal cord injury, heart disease etc.

The Global Induced Pluripotent Stem Cells Market is estimated to be valued at US$ 1,595.4 MN in 2024 and is expected to exhibit a CAGR of 1.4% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Global Induced Pluripotent Stem Cells Market Size  are Takara Bio Inc., Thermo Fisher Scientific, Fujifilm Holdings Corporation, Astellas Pharma, Fate Therapeutics, Ncardia, ViaCyte, Cellular Dynamics International, Lonza, Blueprint Medicines and Other Prominent Players. Takara Bio Inc. is one of the leading players offering iPS cell reprogramming tools, culture media and differentiation kits.

The increasing prevalence of chronic diseases coupled with the rising geriatric population globally is propelling the demand for induced pluripotent stem cells. Their potential to be used as a source for cell therapy and in personalized medicine makes them an attractive option for managing chronic conditions.

Several companies are now expanding their iPSC facilities across major markets to cater to the growing need for regenerative medicines. For instance, Fate Therapeutics established a commercial pluripotent stem cell manufacturing facility in the US while Lonza is setting up cryopreserved iPSC bank facilities in Europe and Japan. This is expected to boost market accessibility over the coming years.

Market drivers

The increasing R&D investments by governments and private organizations in stem cell research are a key growth driver for the global induced pluripotent stem cells market. Between 2010 to 2020, over US$ 30 Bn was invested globally in stem cell-related projects. Continuous funding enables researchers to study regenerative properties of iPSCs for various disease conditions. This is anticipated to escalate therapeutic applications and commercialization of iPSC-based products in the near future.

The ongoing geopolitical issues have created significant challenges for the global induced pluripotent stem cells market growth. With global trade disruptions and economic uncertainties arising due to geopolitical conflicts, it has become difficult for companies engaged in iPSC research and associated activities to maintain steady supply chains and operations. As economies stagnate and funding allocations get diverted to address immediate crises, research investments into new cell therapies also take a hit, thereby negatively impacting the market expansion. Additionally, travel restrictions and policies discouraging global collaboration have hindered knowledge sharing between scientific institutions located across different countries. To sustain growth in such times, business entities need to focus on diversifying their supplier networks, decentralizing manufacturing footprints, and leveraging virtual platforms to continue engaging international expertise. Governments must also prioritize economic stability and ensure adequate public-private investments flow into life sciences innovation.

North America currently accounts for the largest share of the global induced pluripotent stem cells market in terms of value. This is attributed to extensive R&D activities underway, growing stem cell banking facilities, and a supportive regulatory environment driving clinical translation in the region. Additionally, higher healthcare expenditure per capita has enabled pharmaceutical firms and research organizations to channel more funding towards developing advanced cell therapies using iPSC technologies. However, over the forecast period Asia Pacific is anticipated to emerge as the fastest expanding regional market. This can be accredited to rising government and private stakeholder interest in reaping the future economic benefits of regenerative medicine sector in densely populated Asian countries.


Get more insights on Global Induced Pluripotent Stem Cells Market